vs
凯勒威廉姆斯（CTO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
凯勒威廉姆斯的季度营收约是REGENXBIO Inc.的1.4倍（$41.2M vs $30.3M），凯勒威廉姆斯净利率更高（15.1% vs -221.3%，领先236.4%），REGENXBIO Inc.同比增速更快（43.0% vs 15.0%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 19.5%）
凯勒威廉姆斯地产是一家美国科技企业及跨国房地产特许经营商，总部位于得克萨斯州奥斯汀。截至2022年，按销售额计算，它是美国规模最大的房地产特许经营机构，业务覆盖全球多个地区。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CTO vs RGNX — 直观对比
营收规模更大
CTO
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出28.0%
15.0%
净利率更高
CTO
高出236.4%
-221.3%
两年增速更快
RGNX
近两年复合增速
19.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $30.3M |
| 净利润 | $6.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 175.0% | -190.0% |
| 净利率 | 15.1% | -221.3% |
| 营收同比 | 15.0% | 43.0% |
| 净利润同比 | 174.4% | -31.2% |
| 每股收益（稀释后） | $0.13 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTORGNX
| Q1 26 | $41.2M | — | ||
| Q4 25 | $38.3M | $30.3M | ||
| Q3 25 | $37.8M | $29.7M | ||
| Q2 25 | $37.6M | $21.4M | ||
| Q1 25 | $35.8M | $89.0M | ||
| Q4 24 | $35.7M | $21.2M | ||
| Q3 24 | $31.8M | $24.2M | ||
| Q2 24 | $28.8M | $22.3M |
净利润CTORGNX
| Q1 26 | $6.2M | — | ||
| Q4 25 | $28.3M | $-67.1M | ||
| Q3 25 | $2.9M | $-61.9M | ||
| Q2 25 | $-23.4M | $-70.9M | ||
| Q1 25 | $2.3M | $6.1M | ||
| Q4 24 | $-15.2M | $-51.2M | ||
| Q3 24 | $6.2M | $-59.6M | ||
| Q2 24 | $1.2M | $-53.0M |
毛利率CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.4% | — | ||
| Q2 25 | 73.0% | — | ||
| Q1 25 | 75.2% | — | ||
| Q4 24 | 74.4% | 70.2% | ||
| Q3 24 | 74.4% | 48.8% | ||
| Q2 24 | 71.1% | 52.5% |
营业利润率CTORGNX
| Q1 26 | 175.0% | — | ||
| Q4 25 | 75.1% | -190.0% | ||
| Q3 25 | 26.6% | -176.3% | ||
| Q2 25 | -33.7% | -296.3% | ||
| Q1 25 | 22.0% | 13.6% | ||
| Q4 24 | -20.4% | -242.1% | ||
| Q3 24 | 15.6% | -256.6% | ||
| Q2 24 | 18.8% | -251.3% |
净利率CTORGNX
| Q1 26 | 15.1% | — | ||
| Q4 25 | 73.9% | -221.3% | ||
| Q3 25 | 7.7% | -208.3% | ||
| Q2 25 | -62.2% | -331.8% | ||
| Q1 25 | 6.3% | 6.8% | ||
| Q4 24 | -42.6% | -241.3% | ||
| Q3 24 | 19.6% | -246.3% | ||
| Q2 24 | 4.1% | -237.7% |
每股收益（稀释后）CTORGNX
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.81 | $-1.30 | ||
| Q3 25 | $0.03 | $-1.20 | ||
| Q2 25 | $-0.77 | $-1.38 | ||
| Q1 25 | $0.01 | $0.12 | ||
| Q4 24 | $-0.69 | $-0.99 | ||
| Q3 24 | $0.17 | $-1.17 | ||
| Q2 24 | $-0.03 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $575.4M | $102.7M |
| 总资产 | $1.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTORGNX
| Q1 26 | $8.3M | — | ||
| Q4 25 | $6.5M | $230.1M | ||
| Q3 25 | $9.3M | $274.2M | ||
| Q2 25 | $8.6M | $323.3M | ||
| Q1 25 | $8.4M | $267.9M | ||
| Q4 24 | $9.0M | $234.7M | ||
| Q3 24 | $8.2M | $255.5M | ||
| Q2 24 | $4.8M | $290.4M |
总债务CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | $616.3M | — | ||
| Q3 25 | $604.2M | — | ||
| Q2 25 | $605.4M | — | ||
| Q1 25 | $602.2M | — | ||
| Q4 24 | $519.0M | — | ||
| Q3 24 | $526.8M | — | ||
| Q2 24 | $482.7M | — |
股东权益CTORGNX
| Q1 26 | $575.4M | — | ||
| Q4 25 | $567.3M | $102.7M | ||
| Q3 25 | $557.3M | $161.5M | ||
| Q2 25 | $574.1M | $213.7M | ||
| Q1 25 | $593.9M | $274.2M | ||
| Q4 24 | $612.8M | $259.7M | ||
| Q3 24 | $595.8M | $301.4M | ||
| Q2 24 | $491.8M | $348.3M |
总资产CTORGNX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $453.0M | ||
| Q3 25 | $1.2B | $525.2M | ||
| Q2 25 | $1.2B | $581.0M | ||
| Q1 25 | $1.2B | $490.9M | ||
| Q4 24 | $1.2B | $466.0M | ||
| Q3 24 | $1.2B | $519.1M | ||
| Q2 24 | $1.0B | $569.4M |
负债/权益比CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | 1.09× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 0.85× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.98× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | $64.6M | $-52.3M | ||
| Q3 25 | $25.5M | $-56.0M | ||
| Q2 25 | $21.9M | $-49.3M | ||
| Q1 25 | $10.3M | $33.6M | ||
| Q4 24 | $59.9M | $-31.6M | ||
| Q3 24 | $21.2M | $-40.5M | ||
| Q2 24 | $12.9M | $-45.5M |
自由现金流CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M |
自由现金流率CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% |
资本支出强度CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% |
现金转化率CTORGNX
| Q1 26 | — | — | ||
| Q4 25 | 2.28× | — | ||
| Q3 25 | 8.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 4.56× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | 10.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTO
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
